Latent cytokines for targeted therapy of inflammatory disorders
Authors:
- Lisa MullenLMLisa Mullen
- Gill AdamsGAGill Adams
- Lorna LaywardLLLorna Layward
- Sandrine VessillierSVSandrine Vessillier
- Alex AnnenkovAAAlex Annenkov
- Gayatri MittalGMGayatri Mittal
- Anne RigbyARAnne Rigby
- Michelle SclandersMSMichelle Sclanders
- David BakerDBDavid Baker
- David GouldDGDavid Gould
- Yuti ChernajovskyYCYuti Chernajovsky
- 5 October 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 11 (1) , 101-110
Abstract
The use of cytokines as therapeutic agents is important, given their potent biological effects. However, this very potency, coupled with the pleiotropic nature and short half-life of these molecules, has limited their therapeutic use. Strategies to increase the half-life and to decrease toxicity are necessary to allow effective treatment with these molecules. A number of strategies are used to overcome the natural limitations of cytokines, including PEGylation, encapsulation in liposomes, fusion to targeting peptides or antibodies and latent cytokines. Latent cytokines are engineered using the latency-associated peptide of transforming growth factor-β to produce therapeutic cytokines/peptides that are released only at the site of disease by cleavage with disease-induced matrix metalloproteinases. The principles underlying the latent cytokine technology are described and are compared to other methods of cytokine delivery. The potential of this technology for developing novel therapeutic strategies for the treatment of diseases with an inflammatory-mediated component is discussed. Methods of therapeutic cytokine delivery are addressed. The latent cytokine technology holds significant advantages over other methods of drug delivery by providing simultaneously increased half-life and localised drug delivery without systemic effects. Cytokines that failed clinical trials should be reassessed using this delivery system.Keywords
This publication has 82 references indexed in Scilit:
- Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptideAnnals of the Rheumatic Diseases, 2013
- ImmunocytokinesAntibodies, 2012
- A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell CarcinomaClinical Cancer Research, 2011
- Enhanced Expression of CD13 in Vessels of Inflammatory and Neoplastic TissuesJournal of Histochemistry & Cytochemistry, 2011
- Human single‐chain variable fragment that specifically targets arthritic cartilageArthritis & Rheumatism, 2010
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanismsBreast Cancer Research, 2009
- Anti-serum albumin domain antibodies for extending the half-lives of short lived drugsProtein Engineering, Design and Selection, 2008
- Enhancement of therapeutic protein in vivo activities through glycoengineeringNature Biotechnology, 2003
- Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent.Journal of Clinical Investigation, 1996